Health
Secukinumab Has High Retention Rate in Real-World Psoriatic Arthritis Study – AJMC.com Managed Markets Network
New real-world data shows 64% of patients with psoriatic arthritis who had previously been on a biologic stayed on secukinumab for the duration of the study.
A new study suggests secukinumab (Cosenytx) has a high retention rate among biologic-experienced patients with psoriatic arthritis (PsA) in real-world settings, and also produces minimal serious side effects.
The research is important because previous data on the real-world usage of the recombinant human monoclonal antibody has been scarce. The drug, which targets interleukin-17A, has been approved for the treatment of PsA since 2015 in Europe and 2016 in the United States.
A team of Greek inv…
-
General21 hours agoPolice investigating after body found on road in Newborough, Gippsland
-
General11 hours agoMan dies in daylight shooting in Sydney’s north-west
-
Noosa News20 hours agoCouncil steps up staff protection after surge in abuse
-
Business13 hours agoOrd Minnett names 2 ASX 200 shares to buy